ArticleInternational journal of clinical and experimental medicine2015
The C8092A polymorphism in the ERCC1 gene and breast carcinoma risk: a meta-analysis of case-control studies.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Pooled it
- Unlocking the mystery associated with infertility and prostate cancer: an update.Medical oncology (Northwood, London, England) · 2023Review
- Genetic Factors of Non-Obstructive Azoospermia: Consequences on Patients' and Offspring Health.Journal of clinical medicine · 2021Review
- Genetic intersection of male infertility and cancer.Fertility and sterility · 2018Review
- Analysis of DNA Repair Genes Polymorphisms in Breast Cancer.Pathology oncology research : POR · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The C8092A polymorphism in the ERCC1 (excision repair cross-complementation group 1) gene was shown to be associated with breast carcinoma risk. However, the results of different studies remain controversial. A meta-analysis including 3,308 cases and 3,242 controls from eight studies was performed to explore the association between the C8092A polymorphism in the ERCC1 gene and breast cancer risk. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were evaluated by the random effects model. No significant association was detected in an allelic genetic model (OR: 1.081, 95% CI: 0.994-1.175, P=0.068, Pheterogeneity=0.331), a homozygote model (OR: 1.213, 95% CI: 0.926-1.589, P=0.160, Pheterogeneity=0.071), a heterozygote model (OR: 1.061, 95% CI: 0.958-1.176, P=0.256, Pheterogeneity=0.950), a dominant genetic model (OR: 1.082, 95% CI: 0.981-1.193, P=0.113, Pheterogeneity=0.816) and a recessive genetic model (OR: 1.181, 95% CI: 0.904-1.543, P=0.223, Pheterogeneity=0.060) between the C8092A polymorphism in the ERCC1 gene and breast tumor. A significant relationship between the C8092A polymorphism in the ERCC1 gene and breast tumor in Caucasian group was found in a homozygote genetic model (OR: 1.353, 95% CI: 1.009-1.815, P=0.044, Pheterogeneity=0.516) and a recessive genetic model (OR: 1.339, 95% CI: 1.004-1.785, P=0.047, Pheterogeneity=0.532). Individuals with the C8092A polymorphism in the ERCC1 gene have a higher risk of breast cancer in Caucasians, but not for Asians.
Indexed as
Identifiers
26064264PMC4443098W2415826774What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.